150 Participants Needed

Colchicine for Deep Vein Thrombosis

MC
Overseen ByMarc Carrier, MD, MSc
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests whether a low dose of colchicine can prevent post-thrombotic syndrome (pain and swelling after a blood clot) in individuals who have experienced a deep vein thrombosis (DVT) in their leg. Participants will take either colchicine or a placebo (a pill with no active medicine) daily for 180 days. Individuals who have recently experienced their first, painful, and confirmed DVT in the large veins of their leg may be suitable for this study. As a Phase 3 trial, this study represents the final step before FDA approval, allowing participants to contribute to the potential availability of a new treatment.

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are using medications that interact with colchicine, like erythromycin or clarithromycin, you may not be eligible to participate.

Is there any evidence suggesting that colchicine is likely to be safe for humans?

Research has shown that colchicine has been studied for various uses, particularly for heart conditions. A large study tested low-dose colchicine in over 4,700 people with heart disease. Most participants tolerated it well, though some experienced side effects like stomach upset and diarrhea. Serious side effects were rare.

Colchicine is generally considered safe and is approved for conditions like gout and pericarditis (swelling around the heart). However, as with any medication, both the benefits and risks must be considered. Participants in clinical trials help researchers better understand these risks, especially for new uses of colchicine.12345

Why do researchers think this study treatment might be promising for DVT?

Unlike the standard treatments for deep vein thrombosis, which often include anticoagulants like warfarin and direct oral anticoagulants such as rivaroxaban, colchicine offers a unique approach. Colchicine is primarily known for its anti-inflammatory properties, commonly used in conditions like gout, but it may also reduce inflammation in blood vessels, potentially preventing clot formation. Researchers are excited because this anti-inflammatory action could provide an alternative or complementary option with a different mechanism of action, potentially offering benefits in terms of safety and efficacy for patients who cannot tolerate standard anticoagulants.

What evidence suggests that colchicine might be an effective treatment for deep vein thrombosis?

This trial will compare colchicine with a placebo for treating deep vein thrombosis (DVT), a type of blood clot often found in the legs. Research has shown that colchicine might help treat DVT. One study found colchicine more effective than edoxaban, a common blood thinner, for treating DVT in the legs. Colchicine reduces inflammation, which has been shown to lower heart-related problems in other conditions. This suggests it might also reduce inflammation linked to DVT and prevent issues like post-thrombotic syndrome. While more research is needed, these findings offer hope for colchicine's potential benefits for DVT patients.23567

Who Is on the Research Team?

MC

Marc Carrier, MD, MSc

Principal Investigator

Ottawa Hospital Research Institute / Division of Hematology- The Ottawa Hospital

Are You a Good Fit for This Trial?

This trial is for individuals with a recent proximal lower extremity deep vein thrombosis (DVT), which is a type of blood clot in the legs. The full eligibility criteria are not provided, but typically participants must meet certain health conditions and cannot have factors that would exclude them from safely participating.

Inclusion Criteria

I am 18 or older and have a confirmed deep vein thrombosis in my leg.

Exclusion Criteria

I am not taking medications like erythromycin that interact with other drugs.
History of an allergic reaction or significant sensitivity to colchicine
I am currently taking colchicine for a medical condition.
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive colchicine 0.5 mg or placebo daily for 180 days

26 weeks
Regular visits as per study protocol

Follow-up

Participants are monitored for safety and effectiveness after treatment

26 weeks
Follow-up visits at 180 and 365 days

What Are the Treatments Tested in This Trial?

Interventions

  • Colchicine
Trial Overview The study tests if low-dose colchicine (0.5 mg daily) can prevent post-thrombotic syndrome, a complication of DVT, compared to a placebo. It's designed as a pilot for a larger trial and will randomly assign participants to either the medication or placebo group.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Experimental Arm: ColchicineExperimental Treatment1 Intervention
Group II: Control Arm : PlaceboPlacebo Group1 Intervention

Colchicine is already approved in United States for the following indications:

🇺🇸
Approved in United States as Colcrys for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ottawa Hospital Research Institute

Lead Sponsor

Trials
585
Recruited
3,283,000+

Citations

Colchicine therapy for deep vein thrombosis in a patient ...From the course of this case, it was considered that colchicine was more effective than edoxaban, especially for DVT of the lower extremity.
Colchicine in Patients with Chronic Coronary DiseaseEvidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent ...
PROTOCOL LODOCO2 - HeartPrimary Objective. The primary objective of this study is to evaluate clinical efficacy of treatment with colchicine 0.5mg once daily as ...
Colchicine Cardiovascular Outcomes Trial (COLCOT)The study evaluates whether long-term treatment with colchicine reduces rates of cardiovascular events in patients after myocardial infarction.
Colchicine in Cardiovascular Disease: In-Depth ReviewCOLCOT has been the only trial powered enough to investigate improved outcomes from colchicine within a month of an MI. Pooled Efficacy, ...
Balancing the benefits and risks of colchicine use among ...The risks and benefits of colchicine use among patients with atherosclerotic cardiovascular disease (ASCVD) have been widely reported.
TCT-178 Effect of Colchicine on the Cardiovascular ...Recent trials have revealed conflicting data regarding the use of colchicine in the treatment of cardiovascular outcomes for patients with acute coronary ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security